Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study Meeting Abstract
| Authors: | Janjigian, Y. Y.; Ajani, J. A.; Moehler, M.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; Liu, T.; Tehfe, M.; Elimova, E.; Li, M.; Poulart, V.; Lei, M.; Kondo, K.; Shitara, K. |
| Abstract Title: | Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study |
| Meeting Title: | ESMO Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2021 Sep 16-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-09-01 |
| Start Page: | S1329 |
| End Page: | S1330 |
| Language: | English |
| ACCESSION: | WOS:000700527704010 |
| DOI: | 10.1016/j.annonc.2021.08.2131 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA7 -- Source: Wos |
